Germany-based pharmaceutical company Merck KGaA has more than doubled the size of its corporate venturing unit to €100m ($130m). In March 2009, Merck founded its corporate venturing unit – now branded as MS Ventures was – with €40m to invest in early-stage biotechnology companies in oncology, neurodegenerative diseases, fertility, endocrinology and cardiometabolic care. This initial…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
